SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sagimet Biosciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.86+0.84 (+10.47%)
Close on Oct 19, 2026
- Market cap
- $470.59M
- P/E (TTM)
- –
- Dividend yield
- –
Sagimet Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Market Cap | $550.73M | $166.30M |
| Enterprise Value | $293.13M | $88.19M |
| PB Ratio | 2.15 | 2.03 |
| P/TBV Ratio | 2.15 | 2.29 |
Income (trailing twelve months)
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Operating Income | -$52.63M | -$21.40M |
| Net Income | -$47.08M | -$22.46M |
| EBITDA | -$52.63M | -$16.91M |
| EPS (Diluted) | -$1.28 | -$0.83 |
Returns
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -24.4% | -53.2% |
| Return on Assets (ROA) | -23.5% | -40.9% |
| Return on Capital Employed (ROCE) | -20.4% | -38.1% |
Balance sheet
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $257.60M | $61.43M |
| Net Cash (Debt) | $257.60M | $15.35M |
| Net Cash Per Share | $4.14 | $0.66 |
| Equity (Book Value) | $256.16M | $49.09M |
| Book Value Per Share | $4.12 | $1.37 |
| Tangible Book Value | $256.16M | $23.52M |
| Working Capital | $238.57M | $76.81M |
Financial position
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Current Ratio | 45.02 | 3.34 |
| Quick Ratio | 47.54 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$41.72M | -$12.35M |
Efficiency
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Profits Per Employee | -$2.94M | -$703.34K |
| Employee Count | 16 | 74 |
Dividends and yields
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -8.55% | -23.3% |
Shares
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 62,158,700 | 58,127,000 |
| Shares Change (YoY) | 16.9% | 10.9% |
| Float | 60,789,700 | 49,136,700 |
| Shares Held by Insiders | 2.20% | 11.6% |
| Shares Held by Institutions | 82.1% | 59.4% |
Scores
| Measure | Sagimet Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 43.88 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Sagimet Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.